Tazlestobart Biosimilar Monoclonal Antibody (CTLA-4) for Research

Cat No.: GMP-Bios-INN-1409

Anti-CTLA4/CD152 therapeutic antibody (Pre-made Tazlestobart biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture,  assay development,  animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).

Tazlestobart (development code IMM27M) is a humanized monoclonal antibody targeting CTLA-4. It is developed by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. for Oncology, CTLA4 Haploinsufficiency in Phase II development.

Order Information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
Catalog No. Package Price(In USD)
GMP-Bios-INN-1409-1mg 1mg 3090
GMP-Bios-INN-1409-10mg 10mg
GMP-Bios-INN-1409-100mg 100mg
GMP-Bios-INN-1409-xmg ≥100mg



Product Details

Products Name (INN Index) Pre-Made Tazlestobart biosimilar, Whole mAb, Anti-CTLA4/CD152 Antibody: Anti-CTLA-4/CD152/CTLA4/Cytotoxic T-lymphocyte protein 4 therapeutic antibody
INN Name Tazlestobart
Target CTLA4/CD152
Format Whole mAb
Derivation Humanized
Species Reactivity Human
CH1+2+3 Isotype G1
VD LC Kappa
Highest_Clin_Trial (Jan '20) TBC
Est. Status Active
100% SI Structure 5tru:HL:hl/5xj3:AB:DE:JK:GH/6jc2:HL/6rp8:HL:hl/7elx:HL
99% SI Structure None
95-98% SI Structure 7su0:HL:IM/7su1:HL
Year Proposed 2024
Year Recommended 2024
Companies TBC
Conditions Approved TBC
Conditions Active TBC
Conditions Discontinued TBC
Production na
Development Tech na